Angiogenesis-related molecular targets in esophageal cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 5, 2011, Pages 637-644

  Hong, Liu ^a   Li, Shujun ^a   Han, Yu ^a   Du, Jianjun ^a   Zhang, Hongwei ^a   Li, Jipeng ^a   Zhao, Qingchuan ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

angiogenesis; EGFR; esophageal cancer; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CH 806; CISPLATIN; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; MATUZUMAB; MONOCLONAL ANTIBODY IMC 1C11; PACLITAXEL; PANITUMUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ADENOCARCINOMA; ADVANCED CANCER; ANAPHYLAXIS; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TARGETING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTERSTITIAL LUNG DISEASE; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMACH CANCER; THROMBOEMBOLISM; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; ESOPHAGEAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79953672573     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.571203     Document Type: Review

References (58)

1. Shimada Y, Sato F. Molecular factors related to metastasis of esophageal squamous cell carcinoma. Esophagus 2007;4:7-18 (Pubitemid 46475011)
2. Chung CS, Lee YC, Wang CP, et al. Secondary prevention of esophageal squamous cell carcinoma in areas where smoking, alcohol, and betel quid chewing are prevalent. J Formos Med Assoc 2010;109:408-21
3. Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 2009;275:170-7
4. Kumagai Y, Toi M, Kawada K, Kawano T. Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis. Dig Endosc 2010;22:259-67
5. Lo PH, Lung HL, Cheung AK, et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010;70:5567-76
6. Chen L, Di D, Luo G, et al. Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res 2010;30:4363-8
7. Takeuchi K. Prostaglandin EP receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract. Adv Clin Chem 2010;51:121-44
8. Yancopoulos GD. Clinical application of therapies targeting VEGF. Cell 2010;143:13-16 Demonstration that VEGF is suited to the task of cancer therapy.
9. Hong L, Han Y, Li S, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010;10:1693-701
10. Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs 2009;18:1351-64 An overview of the targets in esophageal and gastric cancer.
11. Mitchell DC, Bryan BA. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors. J Cell Biochem 2010;111:543-53
12. Tysome JR, Lemoine NR, Wang Y. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr Opin Mol Ther 2009;11:664-9
13. Evensen L, Link W, Lorens JB. Imaged-based high-throughput screening for anti-angiogenic drug discovery. Curr Pharm Des 2010;16:3958-63
14. Hong L, Fan D. Cancer mucosa antigens: novel immunotherapeutic targets. Expert Opin Ther Targets 2008;12:749-56 An overview of cancer mucosa antigens.
15. Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 2009;15(14):4680-5
16. Tanaka T, Ishiguro H, Kuwabara Y, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010;29:83
17. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010;21:112-17
18. Frentzen A, Yu YA, Chen N, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA. 2009;106:12915-20
19. Ewan S. Black sheep of the VEGF family gives hope for cancer therapy. Drug Discov Today 2005;10:6 (Pubitemid 40164811)
20. Cho DC, Puzanov I, Regan MM, et al. Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. J Immunother 2009;32:181-5
21. Modarai B, Humphries J, Burnand KG, et al. Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution. Arterioscler Thromb Vasc Biol 2008;28:1753-9
22. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007;13:223-30 (Pubitemid 46836870)
23. Black JM, Hodari KT, Rogers N, et al. Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab. Arch Dermatol 2011;147(1):134-5
24. Meza-Junco J, Wong C, Fields A, Sawyer MB. Esophageal ulcer in a patient who received bevacizumab. Invest New Drugs 2010;28(1):98-101
25. Beaumont I. The use of bevacizumab for the treatment of colorectal cancer. Int J Palliat Nurs 2010;16(12):576-78
26. Burns TF, Juergens RA. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient. Oncology (Williston Park) 2010;24(13):1223-4
27. Li J, Merl MY, Chabot J, Saif MW. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010;11:310-2
28. Provencio M, Sánchez A, Garrido P, Valcárcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 2010;11:91-7
29. Blanke CD, Huse DM. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. J Med Econ 2010;13:681-90
30. Pal SK, Figlin RA, Yu H. Deciphering the anticancer mechanisms of sunitinib. Cancer Biol Ther 2010;10:712-14
31. Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5
32. Hou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig 2010;30:799-804
33. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51
34. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16:5489-98
35. Kaneko K, Kumekawa Y, Makino R, et al. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci 2010;15:65-72
36. Pesek M, Benesova L, Belsanova B, et al. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status. Anticancer Res 2009;29:2767-73
37. Kanashiro CA, Schally AV, Zarandi M, et al. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007;30:1019-28
38. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-77 (Pubitemid 47161103)
39. Beydoun SR, Shatzmiller RA. Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment. Clin Neurol Neurosurg 2010;112:900-2
40. Nestor M, Sundstrom M, Anniko M, Tolmachev V. Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas. Nucl Med Biol 2011;38(1):103-12
41. Kuhnt T, Sandner A, Wendt T, et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010;21:2284-9
42. Schmiedel J, Blaukat A, Li S, et al. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008;13:365-73 (Pubitemid 351446197)
43. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80
44. Reck M, van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010;5:1616-22
45. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2010;11(8):1343-57
46. Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front Biosci 2011;3:501-17
47. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19 (Pubitemid 46638785)
48. Li G, Hu W, Wang J, et al. Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010;78:1407-12
49. Bizari L, Borim AA, Leite KR, et al. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 2006;165:41-50 (Pubitemid 43254651)
50. Milano F, Guarriera M, Rygiel AM, Krishnadath KK. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One 2010;5:12424
51. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
52. Lin CC, Yang JC. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs 2011: published online 1 Jan 2011, doi:10.2165/11587560-000000000-00000
53. Looby E, Abdel-Latif MM, Athié-Morales V, et al. Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cells. BMC Cancer 2009;9:190
54. Hu HM, Kuo CH, Lee CH, et al. Polymorphism in COX-2 modifies the inverse association between Helicobacter pylori seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterol 2009;9:37
55. Moons LM, Kuipers EJ, Rygiel AM, et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol 2007;102:2373-9 (Pubitemid 47631756)
56. Lu G, Liu Y, Ji B, et al. Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. Cancer Invest 2010;2:629-34
57. Hong L, Han Y, Zhang H, et al. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010;251:1056-63 Description of the expression pattern of miRNAs in esophageal squamous cell cancer.
58. Rabasseda X, Gomez-Zaera M. A report from the 46th Annual Meeting of the American Society of Clinical Oncology (June 4-8, 1020 - Chicago, Illinois, USA). Drugs Today (Barc) 2010;46:699-731